jiayi-li23/proxann_data huggingface dataset:
Bill 112-S-3560 — Health / R&D
Subject: Health

Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years. Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year. Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer. Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act. Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.
Bill 112-S-3566 — Health / R&D
Subject: Health

Recalcitrant Cancer Research Act of 2012 - Amends the Public Health Service Act to require the Director of the National Cancer Institute (NCI) to develop a scientific framework for research on recalcitrant cancers (cancer with a 5-year relative survival rate below 50%), which includes: (1) a review of the status of research, such as a summary of findings, identification of promising scientific advances, a description of the availability of qualified scientific researchers, and the identification of resources available to facilitate research; (2) identification of research questions that have not been adequately addressed; and (3) recommendations for actions to advance research and for appropriate benchmarks to measure progress on achieving such actions. Requires the Director to develop the framework within 18 months and review and update it every 5 years. Requires the Director to identify within 6 months 2 or more recalcitrant cancers that have a 5-year relative survival rate of less than 20%, and are estimated to cause the death of at least 30,000 individuals in the United States per year. Authorizes the Director to identify additional such cancers and to consider additional metrics of progress (such as incidence and mortality rates) against such cancer. Requires the Director to convene a working group for each identified cancer to provide expertise on, and assist in developing, a scientific framework under this Act. Requires the Director to consider each relevant scientific framework developed under this Act when making recommendations for exception funding for grant applications.
Bill 112-S-3641 — Health / R&D
Subject: Health

Family Asthma Act - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC), to collaborate with state and local health departments to: (1) conduct activities regarding asthma, including deterring the harmful consequences of uncontrolled asthma, and disseminating health education and information regarding prevention of asthma episodes and strategies for managing asthma; and (2) develop state plans incorporating public health responses to reduce the burden of asthma, particularly regarding disproportionately affected populations. Revises and expands requirements for asthma surveillance activities. Requires the Director to coordinate data collection activities to maximize the comparability of results. Requires the Secretary to submit an assessment of current activities related to asthma prevention, management and surveillance along with recommendations for the future direction of asthma activities.
Bill 113-HR-80 — Health / R&D
Subject: Health

Triple-Negative Breast Cancer Research and Education Act of 2013 - Requires the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate programs for the conduct and support of research on triple-negative breast cancer (breast cancers whose cells are negative for estrogen receptors, progesterone receptors, and the HER2 protein on their sources).

Directs the Secretary of Health and Human Services (HHS), acting through the Director of the Centers for Disease Control and Prevention (CDC), to develop and disseminate to the public information regarding triple-negative breast cancer, including information on: (1) the incidence and prevalence of such breast cancer among women, (2) the elevated risk for minority women, and (3) the availability of a range of treatment options.

Requires the Secretary, acting through the Administrator of the Health Resources and Services Administration (HRSA), to develop and disseminate information on triple-negative breast cancer to health care providers.
Bill 113-HR-116 — Health / R&D
Subject: Health

Medical Checklist Act of 2013 - Requires the Director of the Agency for Healthcare Research and Quality, acting through the Center for Quality Improvement and Patient Safety, to conduct a study on the development and efficacy of medical checklists, including: (1) the testing of different models of medical checklists, (2) an examination of checklist development and use in other industries, and (3) a measurement of the effects of the use of medical checklists on patient safety and health outcomes. Requires dissemination of the results of such study to patient safety organizations. Defines "medical checklist" as a predetermined, evidence-based, well-defined set of steps that should be completed during a designated medical clinical encounter or medical procedure.

Requires the Health IT Policy Committee to develop policy recommendations regarding: (1) the extent to which the use of medical checklists should be incorporated into health information technology systems, and (2) measures to determine the effectiveness of such use.

Requires the Secretary to enter into an agreement with the Institute of Medicine and the National Academy of Engineering to conduct a study on medical checklists that includes: (1) a review of available medical checklists and similar quality improvement techniques, (2) an identification of areas of research needed to improve medical checklists, (3) an analysis of organizational impediments to the adoption and use of medical checklists, and (4) a determination of whether the availability of an increased number of medical checklists would improve patient safety and health outcomes.
Bill 113-HR-146 — Health / R&D
Subject: Health

Collaborative Academic Research Efforts for Tourette Syndrome Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH programs and activities regarding Tourette syndrome.

Requires the Director to develop a system to collect data on Tourette syndrome, including epidemiological information regarding its incidence and prevalence in the United States, primary data, and data on the availability of medical and social services for individuals with Tourette syndrome and their families.

 Requires the Director to award grants and contracts to public or nonprofit private entities to pay costs of planning, establishing, improving, and providing basic operating support for between four and six centers of excellence in different regions of the United States to conduct basic and clinical research on Tourette syndrome.

Requires the Director to designate a portion of the amounts made available to carry out NIH programs and activities for a fiscal year to carry out programs and activities with respect to Tourette syndrome.
Bill 113-HR-225 — Health / R&D
Subject: Health

(This measure has not been amended since it was introduced. The summary of that version is repeated here.)

National Pediatric Research Network Act of 2013 - Amends the Public Health Service Act to authorize the Director of the National Institutes of Health (NIH), in carrying out the Pediatric Research Initiative, to act through the Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development to provide for the establishment of a National Pediatric Research Network.

Authorizes the Director of the Institute to award funding to public or private nonprofit entities for: (1) planning, establishing, or strengthening pediatric research consortia; and (2) providing basic operating support for such consortia, including to meet unmet needs for pediatric research through basic, clinical, behavioral, or translational research and the training of researchers in pediatric research techniques. Authorizes the Director of NIH to make awards for not more than 20 pediatric research consortia, which must be formed from a collaboration of cooperating institutions, coordinated by a lead institution, agree to disseminate scientific findings, and meet requirements prescribed by the Director of NIH. Allows such support to be for a period of five years, with additional extensions at the discretion of the Director of NIH.

Requires the Director of NIH to provide for the coordination of activities among the consortia and to require the periodic preparation and submission of reports on their activities. Requires each pediatric research consortium receiving an award to assist the Centers for Disease Control and Prevention (CDC) in the establishment or expansion of patient registries and other surveillance systems as appropriate and upon request by the CDC.

Requires the Director of NIH to ensure that an appropriate number of such awards are awarded to consortia that agree to: (1) focus primarily on pediatric rare diseases or conditions; and (2) conduct or coordinate multi-site clinical trials of therapies for, or approaches to, the prevention, diagnosis, or treatment of pediatric rare diseases or conditions.

Requires the Director of NIH to establish a data coordinating center to: (1) distribute such findings; (2) provide assistance in the design and conduct of collaborative research projects and the management, analysis, and storage of data associated with such projects; and (3) organize and conduct multi-site monitoring activities.

Requires the Director of NIH to: (1) require the data coordinating center to provide regular reports to the Director of NIH and the Commissioner of Food and Drugs (FDA) on research conducted by consortia, including information on enrollment in clinical trials and the allocation of resources with respect to such research; and (2) incorporate such information into NIH's biennial reports.
Bill 113-HR-660 — Health / R&D
Subject: Health

Neuromyelitis Optica Consortium Act - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to establish, administer, and coordinate a National Neuromyelitis Optica (NMO) Consortium to: (1) award grants of not fewer than five years duration to conduct research with respect to the causes of, and the risk factors and biomarkers associated with, NMO (a neurological disease leading to blindness and paralysis); (2) assemble a panel of experts to provide ongoing guidance and the recommendations on research design and protocols, and (3) designate a central laboratory to collect, analyze, and aggregate data with respect to such research and to make such data and analysis available to researchers.

Establishes eligibility requirements for a consortium (a partnership of two or more universities, health care organizations, or government agencies, or any combination of such entities), including that: (1) it has the capability to enroll a minimum of 25 individuals with a diagnosis of NMO as research participants from the designated catchment area (geographical area), and (2) that the catchment area does not overlap with any other consortium receiving a grant under this Act.
Bill 113-HR-842 — Health / R&D
Subject: Health

Functional Gastrointestinal and Motility Disorders Research Enhancement Act of 2013 - Amends the Public Health Service Act to require the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH activities with respect to functional gastrointestinal and motility disorders (FGIMDs), including by: (1) expanding basic and clinical research into FGIMDs by implementing the research recommendations of the National Commission on Digestive Diseases, (2) providing support for the establishment of centers of excellence on FGIMDs, (3) directing the National Institute of Diabetes and Digestive and Kidney Diseases to provide the necessary funding for the continued expansion and advancement of the FGIMDs research portfolio through intramural and extramural research, and (4) directing such Institute and the Eunice Kennedy Shriver National Institute of Child Health and Human Development to expand research into FGIMDs that impact children.

Authorizes the Secretary of Health and Human Services (HHS) to engage in public awareness and education activities to increase understanding and recognition of FGIMDs.
Bill 113-HR-853 — Health / R&D
Subject: Foreign trade and international finance

Citrus Disease Research and Development Trust Fund Act of 2013 - Amends the Trade Act of 1974 to establish the Citrus Disease Research and Development Trust Fund, consisting of revenues from duties paid on imported citrus or citrus products, to support scientific research, technical assistance, and development activities to combat both domestic and invasive citrus diseases and pests harming the United States.

 Establishes the Citrus Disease Research and Development Trust Fund Advisory Board.

Makes Fund amounts available to the Secretary of Agriculture to develop a coordinated program of research and product development relating to: (1) scientific research of both domestic and invasive diseases and pests afflicting the citrus industry; and (2) support for the dissemination and commercialization of relevant information, techniques, and technologies discovered through Fund research or other research projects intended to solve problems caused by citrus production diseases and invasive pests.

Requires the President to notify certain congressional committees before entering into a trade agreement that could result in a decrease in the amount of: (1) duties paid on imported citrus or citrus products, and (2) funds transferred into the Fund.

Prescribes a formula for required estimated tax payments otherwise due in each of the quarters of 2018 from corporations with assets of at least $1 billion.

Amends the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA) to extend certain customs users fees for the processing of merchandise entered into the United States between October 23, 2021, and November 6, 2021, and other specified customs users fees for merchandise entered between October 30, 2021, and November 13, 2021.
Bill 113-HR-1098 — Health / R&D
Subject: Health

Traumatic Brain Injury Reauthorization Act of 2014 - Amends the Public Health Service Act to require the Secretary of Health and Human Services (HHS) to report to Congress on recommendations (made pursuant to an earlier report) concerning improvements in the collection and dissemination of compatible epidemiological studies on the incidence and prevalence of traumatic brain injury in individuals who were formerly in the military, identifying recommendations that have been adopted and describing activities planned to address those that were not adopted.

 Authorizes appropriations through FY2019 for: (1) Centers for Disease Control and Prevention (CDC) projects to reduce the incidence of traumatic brain injury, and (2) traumatic brain injury surveillance systems or registries.

 Authorizes appropriations through FY2019 for the programs of grants to: (1) states and American Indian consortia for projects to improve access to rehabilitation and other services regarding traumatic brain injury, and (2) protection and advocacy systems for the purpose of enabling such systems to provide services to individuals with traumatic brain injury. Removes the Administrator of the Health Resources and Services Administration as agent for the Secretary in administering these programs. Vests responsibility for administering the programs solely in the Secretary.

Requires the Secretary to report to Congress not later than one year after enactment of this Act on the services and activities of the protection and advocacy systems.
Bill 113-HR-1293 — Health / R&D
Subject: Taxation

Taxpayers' Cancer Research Funding Act of 2013 - Amends the Internal Revenue Code to allow taxpayers to designate on their tax returns a $5 contribution to the Breast and Prostate Cancer Research Fund ($10 for joint returns).

Establishes in the Treasury the Breast and Prostate Cancer Research Fund to award grants for breast or prostate cancer research.
Bill 113-HR-1429 — Health / R&D
Subject: Health

Scleroderma Research and Awareness Act of 2013 - Amends the Public Health Service Act to authorize the Director of the National Institutes of Health (NIH) to expand, intensify, and coordinate NIH activities relating to scleroderma, with particular emphasis on: (1) research focused on the etiology of scleroderma and the development of new treatment options; (2) clinical research to evaluate new treatments options; and (3) basic research on the relationship between scleroderma and secondary conditions, such as pulmonary hypertension, gastroparesis, Raynaud's phenomenon, and Sjogren's Syndrome.

Authorizes the Secretary of Health and Human Services (HHS) to carry out an educational campaign to increase public awareness of scleroderma. Permits print, video, and web-based materials distributed through this campaign to include: (1) basic information on scleroderma and its symptoms; and (2) information on the incidence and prevalence of scleroderma, diseases and conditions affiliated with scleroderma, or the importance of early diagnosis and treatment of scleroderma.
Bill 113-HR-1507 — Health / R&D
Subject: Health

Health Outcomes, Planning, and Education for Alzheimer's Act - Amends title XVIII (Medicare) of the Social Security Act to provide for comprehensive Alzheimer's disease diagnosis and services.
Bill 113-HR-1508 — Health / R&D
Subject: Government operations and politics

Directs the United States Postal Service (USPS) to issue and sell an Alzheimer's Disease Research Semipostal Stamp.

Requires proceeds from the sale of the stamp to be transferred to the National Institutes of Health.

Requires the stamp to be made available to the public for six years.
Bill 113-HR-1619 — Health / R&D
Subject: Health

Making Investments Now for Dementia Act of 2013 - Authorizes the Secretary of the Treasury to issue bonds to aid in the funding of Alzheimer's research.

Authorizes appropriations to the Director of the National Institutes of Health (NIH) for such research.

Expresses the sense of Congress that any funds collected pursuant to this Act are in addition to yearly appropriated funds and are not to be used to supplement current funding.
Bill 113-HR-1664 — Health / R&D
Subject: Transportation and public works

Distracted Driving Prevention Act of 2013 - Requires the Secretary of Transportation (DOT) to withhold a certain percentage of a state's apportionment of certain federal-aid highway funds for FY2016-FY2018, and each succeeding fiscal year, if the state has not enacted or is not enforcing a law that: (1) prohibits a driver from using a hand-held personal wireless communications device (such as a cell phone or smart phone) to text or call while driving; (2) allows the use of a hands-free device by a driver (other than a driver who is less than 18 years old) to call; (3) makes violation of the law a primary offense; (4) requires distracted driving issues to be tested as part of the state's driver's license examination; and (5) establishes certain minimum fines and increased civil and criminal penalties.

Excludes from the meaning of personal wireless communications device a global navigation satellite system receiver used for positioning, emergency notification, or navigation (GPS).

Declares that laws meet the requirements of this Act without regard to whether it provides exceptions for driver: (1) use of a cell phone in emergency situations, and (2) use of a cell phone to activate its hands-free capabilities.

Requires the Secretary to establish a research program to study distracted driving by passenger and commercial vehicle drivers.

Directs the the Federal Communications Commission (FCC) to report to Congress on existing and developing wireless communications technology that may be used to reduce problems associated with distracted driving.
Bill 113-HR-1740 — Health / R&D
Subject: Health

Patients First Act of 2013 - Amends the Public Health Service Act to require the Secretary of Health and Human Services to conduct and support basic and applied research to develop techniques for the isolation, derivation, production, testing, and human clinical use of stem cells that may result in improved understanding of, or treatments for, diseases and other adverse health conditions, including pluripotent stem cells that have the flexibility of embryonic stem cells (whether or not such pluripotent stem cells have an embryonic source), provided that such techniques will not involve: (1) the creation of a human embryo for research purposes; (2) the destruction or discarding of, or risk of injury to, a living human embryo; or (3) the use of any stem cell the derivation or provision of which would be inconsistent with this Act.

Requires the Secretary to issue guidelines implementing this Act to ensure that any research (including any clinical trial) supported under this Act: (1) is clearly consistent with the standards established in this Act, if conducted using human cells; and (2) is prioritized in terms of potential for near-term clinical benefit in human patients.

Requires the Secretary to report on peer reviewed stem cell research proposals that were not funded.
Bill 113-HR-1830 — Health / R&D
Subject: Health

Accelerating the End of Breast Cancer Act of 2013 - Directs the President to establish the Commission to Accelerate the End of Breast Cancer to help end breast cancer by January 1, 2020.

Directs the Commission to: (1) identify opportunities and ideas within government and the private sector that are key components in achieving the end of breast cancer and which have been overlooked, yet are ripe for collaboration and investment; (2) recommend projects to leverage such opportunities and ideas in the areas of the primary prevention of breast cancer and the causes and prevention of breast cancer metastasis; and (3) ensure that its activities are coordinated with, and do not duplicate the efforts of, programs and laboratories of other government agencies.

Directs the President to enter into an agreement with the Institute of Medicine for an evaluation of the Commission's progress.

Terminates the Commission on June 1, 2020.